In Vitro Activity of Fosfomycin in Double and Triple Combinations with Imipenem, Ciprofloxacin and Tobramycin Against Multidrug-Resistant Escherichia coli
- PMID: 31919670
- DOI: 10.1007/s00284-019-01871-w
In Vitro Activity of Fosfomycin in Double and Triple Combinations with Imipenem, Ciprofloxacin and Tobramycin Against Multidrug-Resistant Escherichia coli
Abstract
The rates of urinary tract infection with multidrug-resistant (MDR) Escherichia coli have dramatically increased and the treatment of these infections with single and double antibiotic combinations became limited or ineffective. The present study aimed at finding effective antibiotic combinations against MDR uropathogenic E. coli. Antibiotic susceptibility testing of uropathogenic E. coli isolates (n = 29) showed that all the examined isolates were found to be MDR. The interaction of double and triple combinations of fosfomycin (FOS) with imipenem (IPM), ciprofloxacin (CIP) and tobramycin (TOB) against selected isolates (n = 8) by checkerboard method showed that all the examined combinations exhibited synergistic effects (FIC index < 1) against tested isolate. However, 1/8, 5/8 and 6/8 of the isolates remained resistant to the constituent antibiotics in FOS/IPM, FOS/CIP and FOS/TOB combinations, respectively. Notably, the triple combinations (FOS/IPM/CIP, FOS/IPM/TOB and FOS/CIP/TOB) increased the synergism against all selected isolates at MIC levels lower than the susceptible breakpoints. Furthermore, time-kill analysis demonstrated that FOS/IPM combination exhibited synergistic and bactericidal effects with UTI-9. However, the combination had no effect on UTI-13. The highest synergistic and bactericidal effects against both representative isolates were achieved by FOS/IPM/CIP, FOS/IPM/TOB and FOS/CIP/TOB combinations after 2 h of post-treatment and lasted up to 24 h. Therefore, we report here that the combinations of FOS with IPM, CIP and TOB could be beneficial against MDR uropathogenic E. coli at least in vitro. The effectiveness of these antibiotics increased in combination with FOS compared to individual antibiotics acting alone.
Similar articles
-
Time kill-assays of antibiotic combinations for multidrug resistant clinical isolates of OXA-48 carbapenemase producing Klebsiella pneumoniae.Acta Microbiol Immunol Hung. 2022 Jun 14;69(3):215-219. doi: 10.1556/030.2022.01785. Print 2022 Sep 16. Acta Microbiol Immunol Hung. 2022. PMID: 35895557
-
Chimeric Tobramycin-Based Adjuvant TOB-TOB-CIP Potentiates Fluoroquinolone and β-Lactam Antibiotics against Multidrug-Resistant Pseudomonas aeruginosa.ACS Infect Dis. 2023 Apr 14;9(4):864-885. doi: 10.1021/acsinfecdis.2c00549. Epub 2023 Mar 14. ACS Infect Dis. 2023. PMID: 36917096
-
An in vitro experimental study of the effect of fosfomycin in combination with amikacin, ciprofloxacin or meropenem on biofilm formation by multidrug-resistant urinary isolates of Escherichia coli.J Med Microbiol. 2019 Dec;68(12):1699-1706. doi: 10.1099/jmm.0.001061. Epub 2019 Oct 18. J Med Microbiol. 2019. PMID: 31647407
-
Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.Int J Antimicrob Agents. 2009 Aug;34(2):111-20. doi: 10.1016/j.ijantimicag.2009.03.009. Epub 2009 Apr 28. Int J Antimicrob Agents. 2009. PMID: 19403273 Review.
-
Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and Enterobacterales.Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0144621. doi: 10.1128/AAC.01446-21. Epub 2021 Nov 22. Antimicrob Agents Chemother. 2022. PMID: 34807759 Free PMC article. Review.
Cited by
-
Repurposing carvacrol, cinnamaldehyde, and eugenol as potential anti-quorum sensing agents against uropathogenic Escherichia coli isolates in Alexandria, Egypt.BMC Microbiol. 2023 Oct 23;23(1):300. doi: 10.1186/s12866-023-03055-w. BMC Microbiol. 2023. PMID: 37872476 Free PMC article.
-
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022. Front Public Health. 2022. PMID: 36620240 Free PMC article. Review.
-
Synergistic activity and molecular modelling of fosfomycin combinations with some antibiotics against multidrug resistant Helicobacter pylori.World J Microbiol Biotechnol. 2022 Apr 29;38(6):102. doi: 10.1007/s11274-022-03289-2. World J Microbiol Biotechnol. 2022. PMID: 35486219 Free PMC article.
-
Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem-Resistant Acinetobacter baumannii.Pharmaceuticals (Basel). 2021 Feb 25;14(3):185. doi: 10.3390/ph14030185. Pharmaceuticals (Basel). 2021. PMID: 33668905 Free PMC article.
-
Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers.Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01375-20. doi: 10.1128/AAC.01375-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33106259 Free PMC article. Clinical Trial.
References
-
- Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Apr 1;68(Pt 4):382-5 - PubMed
-
- Antimicrob Agents Chemother. 1995 May;39(5):1038-44 - PubMed
-
- J Antimicrob Chemother. 2005 May;55(5):699-706 - PubMed
-
- Pediatr Pulmonol. 2005 Jan;39(1):15-20 - PubMed
-
- Antimicrob Agents Chemother. 2008 Oct;52(10):3820-2 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
